IRIDEX Co. (NASDAQ:IRIX) insider Romeo R. Dizon sold 2,806 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $5.86, for a total value of $16,443.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NASDAQ:IRIX opened at $5.67 on Friday. IRIDEX Co. has a 12-month low of $5.31 and a 12-month high of $12.43. The company has a market capitalization of $66.51, a price-to-earnings ratio of -5.11 and a beta of 1.40.
IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Thursday, March 8th. The medical equipment provider reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.17). IRIDEX had a negative net margin of 30.93% and a negative return on equity of 35.98%. The company had revenue of $10.24 million during the quarter, compared to analyst estimates of $10.22 million. equities research analysts predict that IRIDEX Co. will post -1.14 EPS for the current fiscal year.
Separately, Zacks Investment Research raised IRIDEX from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th.
Institutional investors have recently bought and sold shares of the company. Neuberger Berman Group LLC purchased a new stake in shares of IRIDEX in the third quarter valued at approximately $141,000. Deutsche Bank AG increased its position in shares of IRIDEX by 31.6% in the fourth quarter. Deutsche Bank AG now owns 35,430 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 8,509 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of IRIDEX by 12.8% in the fourth quarter. Renaissance Technologies LLC now owns 272,900 shares of the medical equipment provider’s stock valued at $2,079,000 after buying an additional 31,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of IRIDEX by 0.4% in the second quarter. Vanguard Group Inc. now owns 392,317 shares of the medical equipment provider’s stock valued at $3,880,000 after buying an additional 1,731 shares in the last quarter. Finally, Lyon Street Capital LLC increased its position in shares of IRIDEX by 4.5% in the third quarter. Lyon Street Capital LLC now owns 442,647 shares of the medical equipment provider’s stock valued at $4,148,000 after buying an additional 19,059 shares in the last quarter. Institutional investors and hedge funds own 48.18% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Romeo R. Dizon Sells 2,806 Shares of IRIDEX Co. (IRIX) Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/iridex-co-irix-insider-romeo-r-dizon-sells-2806-shares.html.
IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.